Epsilon M&A Deal Report - Xellia Group (Xellia Pharmaceuticals)
Transaction Multiples for the Valuation of Private Companies
Private Group led by Novo A/S / Xellia Group (Xellia Pharmaceuticals)
No EMAT :
62943
Announced Date :
21/05/2013
Type :
SBO (Secondary Buy Out) ,Exit
Deal Value :
Yes
Acquirer :
Private Group led by Novo A/S
Target :
Xellia Group (Xellia Pharmaceuticals)
Country :
Norway
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Xellia Pharmaceuticals AS is a fully integrated specialty pharmaceutical company focusing on the global anti-infective market , with over 100 years of experience and expertise in the supply of...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
ns | |||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
| Date | Acquirer | Target | Country | Multiples | See details |
| 30/09/2013 | Aspen Pharmacare Holdings | Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant | France | ** | 62935 |
| 22/05/2013 | Private Group led by Charterhouse Capital Partners LLP | DOC Generici | Italy | *** | 62906 |
Source: Epsilon Research / EMAT
